UC San Diego Health Sciences schools, institutes and centers are at the forefront of discovery and transformation.
UC San Diego Research Affairs –The Office of Innovation and Commercialization launches the first of an eighteen-month entrepreneurial seminar series, free and open to anyone at UC San Diego and the general public, including members of any other research institutions, Mar. 9.
Researchers at the Skaggs School of Pharmacy and Pharmaceutical Sciences at UC San Diego are running a Diabetes Intensive Medical Management (DIMM) “tune up” clinic for complex type 2 diabetes patients. In a study published in the March 2017 issue of the Journal of Managed Care & Specialty Pharmacy, the researchers report the clinic’s economic benefits, which include an estimated cost avoidance of $5,287 per DIMM clinic patient over three years.
Thanks to local and regional elected officials who helped assure passage of Assembly Bill 2664, the University of California San Diego has received $2.2 million from the UC system to help spur innovation and entrepreneurship on campus.
The next presentation in UC San Diego’s “Inside Innovation” series features Dr. Catriona Jamieson speaking on “Detection and Therapeutic Targeting of Cancer Stem Cell Evolution.” The free and public presentation will be held 4-6 p.m. on Tuesday, Jan. 17, in Roth Auditorium at the Sanford Consortium for Regenerative Medicine, 2880 Torrey Pines Scenic Drive. A networking reception will follow.
The innovation ecosystem at UC San Diego will open more opportunities for campus entrepreneurs with the launch of Accelerating Innovations to Market (AIM), an ambitious program that encourages graduate students, postdoctoral scholars, researchers and faculty to develop and commercialize their problem-solving ideas.
Researchers at the Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego have now determined the 3D structure of CCR2 simultaneously bound to two inhibitors. Understanding how these molecules fit together may better enable pharmaceutical companies to develop anti-inflammatory drugs that bind and inhibit CCR2 in a similar manner. The study is published December 7 by Nature.
Forbes, May 29
San Diego Union Tribune, May 28
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
